$40 – $55

ANOTHER FUNDING ROUND, AN IPO, OR EXIT? WHAT SHOULD WE DO?

Event Information

Share this event

Date and Time

Location

Location

Meeting Space Provided by DeviceTalks2018

@ Westin Boston Waterfront

425 Summer St

Boston, Massachusetts 02210

View Map

Refund Policy

Refund Policy

Refunds up to 1 day before event

Event description

Description

ANOTHER FUNDING ROUND, AN IPO, OR EXIT? WHAT SHOULD WE DO?


Our meeting space is being provided by DeviceTalks 2018

DeviceTalks 2017

Westin Boston Waterfront | 425 Summer St | Boston, MA 02210

For Driving and Parking Information, click here.



Program Description:

Your firm has revenues and a level of market acceptance and success. But the firm cannot grow to its full potential without significantly more capital. Your board and senior leadership team must decide whether to raise more capital with a new investment round, do an IPO, or look for a buyer for the company.

CEOs from different segments of the med tech and pharma space who have made these hard decisions will share their experiences. The interests of the founders and current investors must be considered. Control of the company will change.

  • How do the alternative financing paths change the risks and potential for achieving the company's potential value?
  • What is the market for raising funds or M&A, where will they be in 2 - 3 years?
  • What will be the role of the current management team and board under the different scenarios?

You will learn how our panel considered these factors and others when they had to decide which path to take for their company. And how did their decisions work out?

Keynote Speaker:

Walter Beinecke

Walter Beinecke, Partner, Board Member, Member of Investment Committee, Brook Venture Partners

Walter is passionate about investing, supporting and partnering with management teams at expansion stage companies.

Special Introduction and Panel Moderated by:

Rick Williams, Managing Director, Williams Advisory Partners

Rick is a CEO and board advisor. Nationally published thought leader on preparing to raise capital, overcoming barriers to growth and preparing for the sale of the company.

Panelists:

Adam Gridley, President & CEO of Histogenics Corporation

Adam has over 20 years of transactional and operational experience in venture capital backed and public medical device, and pharmaceutical companies.

Eamonn Hobbs, Chairman and CEO, ImmunSYS

Eamonn has had tremendous success in creating long-lasting innovative endeavors and growing them into strong financially performing companies.

E. James Hutchens, CEO, President, Director, ImaginMedical

Jim Hutchens is a proven entrepreneur with over 30 years of experience in general management in the medical technology industry.

Peter Savas, CEO & Chairman, LikeMinds

Peter is a serial entrepreneur, strategic planner, value-added investor, executive chairman, director & advisor.

Come join this timely, lively, keynote presentation and blue-ribbon panel discussion. Ask questions and contribute your insights during the audience interactive segment.

Who should attend?

CEOs, board members, investors, and other senior leaders who want a better understanding of how to make important decisions at strategic inflection points for the company.



NOTE: This month's meeting is in concurrence with DeviceTalks Boston 2018. Following our meeting, participants are invited to the DeviceTalks Exhibition and Networking Break at 10am.

40% discount registration to DeviceTalks is available using promotional code “NE40”.



Speaker Biographies:

Walter Beinecke, Partner, Board Member, Member of Investment Committee, Brook Venture Partners

Walter is passionate about supporting and partnering with management teams. Walter is an enthusiastic advocate for effective governance and serves as the Chairman of the Board for RobbinsKersten Direct, Allegiance Group, and Coronis Health. He also serves as a Director on the boards of Orbis Technologies and FarmMarketiD. Walter is the President of the Board of Osceola Foundation, a charitable foundation focused on the conservation, preservation, and stewardship of Nantucket Island.

Prior to joining the venture field, Walter had a 20 year career as an operating executive. He has served as CEO, President, and/or EVP of seed and expansion stage companies from inception to over $50 million/year in revenue. At Brook he offers portfolio companies counsel and mentoring in sales, business development, and overall strategy based on his operating background. He specializes in helping Brook companies implement sales & marketing strategies that accelerate predictable revenue growth.

Adam Gridley, President & CEO of Histogenics Corporation

Adam has been President & CEO of Histogenics Corporation (Nasdaq: HSGX) since May 2014. Since joining Histogenics, Mr. Gridley recruited a new leadership team who has executed a successful clinical and manufacturing strategy to prepare its lead regenerative biologic product for a planned BLA filing in 2018 or 2019, raised over $100 M for the Company, and completed a seminal Japanese licensing partnership valued at ~$90 M. Before joining the Histogenics team, Mr. Gridley served in several senior roles of increasing responsibility at Merz, a privately-held specialty healthcare company focused on the development and commercialization of products for aesthetics, dermatology and neurosciences, where he was most recently Senior Vice President of Technical Operations. During his time at Merz, he served as the global site head responsible for a variety of functions, including R&D, Manufacturing, Quality Operations, Finance and IT. Previously, Mr. Gridley was Senior Vice President of Corporate Development for BioForm Medical, Inc. a publicly-traded company that was acquired by Merz in 2010. His responsibilities included all business development, investor relations, strategic planning, and R&D functions, and he was part of the leadership team who led the Company’s IPO and subsequent acquisition by Merz. Mr. Gridley has held several key strategic leadership roles in the orthopedics space during his career including Director of Business Development and Investor Relations at Gliatech Inc. Mr. Gridley holds a Bachelor of Science and a Master of Business Administration from the University of Denver.

Eamonn Hobbs, Chairman and CEO, ImmunSYS

Eamonn Hobbs has had tremendous success in creating long lasting innovative endeavors and growing them into strong financially performing companies. His greatest achievement to date was AngioDynamics, Inc. which he founded as a division of a public parent company, E-Z-EM, Inc. (NASDAQ: EZEM), and lead it through a value creating carve out tax-free spin-off and simultaneous IPO, (NASDAQ: ANGO). AngioDynamics, Inc. became the best performing medtech IPO of 2004, and continued to demonstrate award winning performance throughout Mr. Hobbs tenure. Mr. Hobbs continued to grow it as a top performing public company well past $220 million in organic revenues. AngioDynamics is a market leader in image guided therapeutic devices, drug delivery devices and combination drug/device products utilized in cardio and peripheral vascular medicine, cosmetic medicine, and oncology.

Since leaving AngioDynamics in 2009 Mr. Hobbs has served on many public and private company Boards, two of which asked him to become CEO. In 2016 Mr. Hobbs revitalized his healthcare consulting company, Hobbs Medical Ventures, LLC. www.hobbsmv.com which focuses on providing solutions to medical device, pharmaceutical and combination drug/device companies. Mr. Hobbs currently serves on the Board of OraSure Technologies (NASDAQ: OSUR), a leader in the field of oral sample diagnostics products, Harmonic Medical, Inc., a Toronto based private company developing the worlds first ultrasound guided HIFU (high intensity focused ultrasound) with an initial application for physician office based fibroid ablations, and is Chairman of the Board of Marvao Medical, a Galway, Ireland based company developing NexSite, a new technology that materially reduces CRBSI (Catheter Related Blood Stream Infections) in long term indwelling vascular access catheters.

In January of 2018, Mr. Hobbs co-founded and became Chairman and CEO of ImmunSYS, Inc., a clinical stage immunotherapeutic drug and device company focused on the development of a new late stage metastatic prostate cancer therapy system called MyVaccx™. The MyVaccx therapy is designed to empower the patient’s own immune system to fight off cancer. It achieves this via a focal treatment of the solid tumor via a proprietary antigen presentation medical device system, immediately followed by the intra-tumoral injection of a proprietary immunotherapeutic drug formulation. The immune system then is expected to immediately create an autologous vaccine that attacks the cancer throughout the body.

E. James Hutchens, CEO, President, Director, ImaginMedical

Jim Hutchens is a proven entrepreneur with over 30 years of experience in general and marketing management in the medical technology industry. Mr. Hutchens served as a Managing Partner in Origin Partners, a $55 million early stage, venture capital fund and was the founder and CEO of both Microsurge Inc., a venture-backed, minimally invasive surgery company, and Choice Therapeutics, an advanced wound-care company which was sold to Alliqua Biomedical a NASDAQ list company. Mr. Hutchens also served in senior executive positions at Microvasive Endoscopy, a division of Boston Scientific, Smith & Nephew, and Millipore. He is a former member of the Board of Directors of the Brigham and Womens/ Faulkner Hospital and holds a BS in Business Administration from Boston University.

Peter Savas, CEO & Chairman, LikeMinds

Peter Savas is CEO of LikeMinds, bringing 30 years in executive leadership positions across life sciences. He was CEO of Alseres Pharmaceuticals, Inc., Chairman and CEO of Aderis Pharmaceuticals, developer of the Neupro® transdermal patch marketed worldwide to treat Parkinson’s disease and Restless Legs Syndrome and Chairman and CEO of Unisyn, a cGMP contract manufacturer of biologics for clinical trials. Peter also held executive and operating leadership positions with Bristol Meyers, Waters, Millipore, Genex and Zymark.

With a personal mission for entrepreneurism and pursuing advancement in neurologic science, Peter bridges strategic and operational healthcare experience with broad access to industry, academia, regulatory and capital markets leaders. Peter holds a BS in Chemistry from Syracuse University and is credentialed as a Professional Director by the American College of Corporate Directors.

Peter has been an independent director and executive chairman of private and public companies. He is currently the Chairman of the National Research Council of the Kennedy Krieger Institute for children with neurological disorders. He is also a Strategic Partner of SV Life Science Funds 3, 4 and 5.

Rick Williams, Managing Director, Williams Advisory Partners, LLC

Rick is Managing Director of Williams Advisory Partners, LLC. He has a breadth of experience as an executive and board director for technology companies including medical technology and financial services. Williams Advisory Partners provides CEO and board advisory services for middle market technology companies. Rick founded and was President of The Equity Company, an award winning multifamily real estate investment and development company. He was Chairman of the Board of Point Care Technologies and formerly was Chairman of a quasi-public bank/VC firm providing financing to companies with limited access to conventional financing. Rick is past President of the Harvard Business School Association of Boston. He was a management consultant with the global consulting firm Arthur D. Little, Inc., working on business strategy and acquisitions and the economic and strategic impact of government policy and regulations on a broad spectrum of industries. Before that, he was a physicist with Itek Corp, where he developed space and defense related photo & electro/optical systems.


SPONSORSHIP KINDLY PROVIDED BY:


DeviceTalks 2017









Share with friends

Date and Time

Location

Meeting Space Provided by DeviceTalks2018

@ Westin Boston Waterfront

425 Summer St

Boston, Massachusetts 02210

View Map

Refund Policy

Refunds up to 1 day before event

Save This Event

Event Saved